Fractyl Health
Update in progressGUTS (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Fractyl Health, Inc. is a metabolic therapeutics company focused on treatments for type 2 diabetes and obesity. It develops Revita DMR System, an outpatient procedure aimed at durably correcting duodenal dysfunction linked to high-fat, high-sugar diets. It also is advancing Rejuva, an adeno-associated virus–based pancreatic gene therapy platform intended to induce long-term remission by altering islet hormone function. Formerly Fractyl Laboratories, renamed in 2021. Founded 2010, based in Burlington, MA.
Company score
- Sentiment
- 0.36
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.27
- Governance
- 0.10
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.10
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.23
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEODr. Harith Rajagopalan M.D., Ph.D.
- Founded2010
- Employees100
- Websitefractyl.com
Identifiers
- ISINUS35168W1036
- FIGIBBG002Y7NH72
- CUSIP35168W103
- CIK0001572616